Sangamo BioSciences | SGMO - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
Alaunos Therapeutics USD -1.13M 1.11M 2024-09
Alnylam Pharmaceuticals USD 825M 4.3M 2026-03
Amgen USD 6.89B 415M 2025-12
Bayer EUR 6.94B 1.58B 2025-12
BioCryst Pharmaceuticals USD 153.05M 4.16M 2025-12
Biogen USD 1.82B 169.5M 2026-03
BioMarin Pharmaceutical USD 571.21M 141.8M 2026-03
Cipla INR 39.1B 2.54B 2026-03
Clal Biotechnology ILS -857K 1.42M 2022-06
Compugen USD 63.8M 63.56M 2025-12
CSL USD 4.46B 2.71B 2025-12
Gilead Sciences USD 5.52B 791M 2026-03
GlaxoSmithKline GBP 5.75B 429M 2026-03
Grifols EUR 766.49M 39.74M 2024-12
Ionis Pharmaceuticals USD 243M 48M 2026-03
J&J USD 17.24B 642M 2026-03
Karyopharm Therapeutics USD 32.6M 63.38M 2025-12
Merck USD 10.85B 2.57B 2025-12
Novartis USD 10.07B 184M 2026-03
Omeros USD -33.16M 18.52M 2024-06
Pfizer USD 11.04B 1.24B 2026-03
Roche Holding CHF 22.09B 10.04B 2025-12
Sangamo BioSciences -2.39M 1.09M 2024-06
Sanofi EUR 8.45B 1.31B 2025-12
Sarepta Therapeutics USD 621.34M 577.79M 2026-03
Tectonic Therapeutic USD 0 0 2025-03
Ultragenyx Pharmaceutical USD 106M 72M 2026-03
Vertex Pharmaceuticals USD 2.6B 121.7M 2026-03